US Patent

US9126941 — Treatment of hyperproliferative disorders with diarylhydantoin compounds

Method of Use · Assigned to University of California San Diego UCSD · Expires 2026-05-15 · 0y expired

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects diarylhydantoin compounds, including diarylthiohydantoins, for use in treating hormone refractory prostate cancer.

USPTO Abstract

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

Drugs covered by this patent

Xtandi (enzalutamide) · Astellas Pharma

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2708`	—	Xtandi
`U-2708`	—	Xtandi
`U-2345`	—	Xtandi

Patent Metadata

Patent number: US9126941
Jurisdiction: US
Classification: Method of Use
Expires: 2026-05-15
Drug substance claim: No
Drug product claim: No
Assignee: University of California San Diego UCSD
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.